NCT06361576已完成不适用
Patients With Upper Gastrointestinal Adenocarcinoma Enrolled in a Patient Support Program to Receive Nivolumab in the Metastatic Setting: Real-World Data From Canada
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 700 人开始时间: 2023年9月5日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 700
- 试验地点
- 1
- 主要终点
- Particpant sociodemographics
研究概览
简要总结
The purpose of this observational study is to describe the demographics, and disease characteristics of participants with metastatic upper gastrointestinal cancer, along with the treatment characteristics of these patients when treated with nivolumab.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Enrolled in the Bristol-Myers Squibb GastroEsophageal Opdivo in non-Resectable, advanced or metastatic Adenocarcinoma Patient Support Program (GEORgiA PsP) in Canada
- •Have consented to the use of their de-identified data generated from information collected during the course of the GEORgiA PsP
排除标准
- •Aged <18 years
- •HER2 positive status
- •Untreated brain metastases
研究组 & 干预措施
Participants enrolled and treated with nivolumab in the metastatic setting
干预措施: Nivolumab (Drug)
结局指标
主要结局
Particpant sociodemographics
时间窗: Baseline
Participant comorbidities
时间窗: Baseline
Participant tumour location
时间窗: Baseline
Participant treatment history
时间窗: Baseline
Participant Eastern Cooperative Oncology Group (ECOG) score
时间窗: Baseline
Participant HER2 status
时间窗: Baseline
次要结局
- Participant adverse events (AEs)(Up to 75 weeks)
- Management of participant adverse events (AEs)(Up to 75 weeks)
- Initial nivolumab dosage prescribed to participants(Index date)
- Number of nivolumab treatments received by participants(Up to 75 weeks)
- Planned combination chemotherapy treatment(Index date)
- Nivolumab treatment initiation date(Index date)
- Nivolumab dosage modification(Up to 75 weeks)
- Participant treatment duration(Up to 75 weeks)
- Reason for participant discharge(Up to 75 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in CanadaUpper Gastrointestinal CancerNCT06361563Bristol-Myers Squibb250
进行中（未招募）
不适用
GastroIntestinal Cancer in Children and AdolescentsGastrointestinal CancerBurkitt LymphomaNeuroendocrine TumorsHepatocellular CarcinomaGastric CancerHepatoblastomaColorectal CancerNCT05693519Paul G. Kemps, MD2,500
尚未招募
不适用
Prospective Observational Cohort StudyLiver MetastasesGastric CancerNCT06493448Lin Chen1,326
终止
不适用
Demographics and Findings of Upper Endoscopy PatientsBarrett EsophagusGastroesophageal RefluxNCT00576992Midwest Biomedical Research Foundation1,177
撤回
不适用
Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)GastroEsophageal CancerNCT06283238Duke University500